Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0.36) Estimate, Sales $14.415M Beat $13.095M Estimate
Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0.36) Estimate, Sales $14.415M Beat $13.095M Estimate
Exagen 2024年第一季度GAAP每股收益美元（0.19美元）超过预期（0.36美元），销售额为1441.5万美元，超过预期的1,309.5万美元
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.22 percent. This is a 56.82 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $14.415 million which beat the analyst consensus estimate of $13.095 million by 10.08 percent. This is a 28.36 percent increase over sales of $11.230 million the same period last year.
Exagen（纳斯达克股票代码：XGN）公布的季度亏损为每股0.19美元，比分析师普遍预期的0.36美元（0.36美元）高出47.22％。这比去年同期每股亏损0.44美元（0.44美元）增长了56.82％。该公司公布的季度销售额为1441.5万美元，比分析师普遍预期的1,309.5万美元高出10.08％。这比去年同期的112.30万美元的销售额增长了28.36％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。